drugset
drugset / Trial / NCT05619536

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

NCT05619536 ↗

Phase 1 Completed 28 enrolled Cidara Therapeutics Inc. Janssen Pharmaceuticals · collab
RandomizedSequentialQuadruple-blindPrevention

Summary

The purpose of this study is to determine the safety and tolerability profile of CD388 Injection, as compared to saline placebo, when dosed by subcutaneous (SQ) administration as a single dose to healthy Japanese adult subjects.

Timeline

Start
2022-10-18
Primary completion
2023-07-14
Completion
2023-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject CD388 Other / unclassified 50 mg Subcutaneous
Subject CD388 Other / unclassified 150 mg Subcutaneous
Subject CD388 Other / unclassified 450 mg Subcutaneous

Indications

No indication recorded.